Vaccibody – a novel generation of vaccines

Vaccibody is a vaccine company dedicated to the development of novel vaccines that has the potential to overcome shortcomings of current vaccine technology. Based on its proprietary vaccine technology, Vaccibody is developing several vaccine candidates against cancer and chronic infections. Through preclinical studies we have established a vaccine technology which induces strong immunological responses even with weak antigens.

 

Effectively overcome the challenges faced in vaccine design and delivery for further progress in the clinic

 

marcus evans life sciences is delighted to announce that Ole Henrik Brekke will be speaking at our Gene based Vaccines: Optimising Development and Delivery conference on the 13th and 14th of September 2010 in Vienna, Austria.

Read more...
 
Vaccibody In Genetic Engineering News

In the December issue of Genetic Engineering News, Vaccibody is presented in the article "Big Pharma's Interest in Vaccine Products on Rise".

The article is based on the talk given by CEO, Ole Henrik Brekke at the World Vaccine Congress, Lyon October 2009.